Peginterferon alfa-2a (40 kd) and ribavirin for Black American patients with chronic HCV genotype 1

Hepatology

Volumn 39, Issue 6, 2004, Pages 1702-1708

  Jeffers, Lennox J ^a,f   Cassidy, William ^b   Howell, Charles D ^c   Hu, Sylvia ^d   Reddy, K Rajender ^e  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b LOUISIANA STATE UNIVERSITY   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d HOFFMANN LA ROCHE INC   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA;

ABDOMINAL PAIN; ADULT; AFRICAN AMERICAN; ALOPECIA; ANOREXIA; ARTHRALGIA; ARTICLE; BACKACHE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEPRESSION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG RESPONSE; DRY SKIN; DYSPNEA; ERYTHEMA; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; GENOTYPE; HEADACHE; HEPATITIS; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; HUMAN TISSUE; INSOMNIA; IRRITABILITY; LIVER BIOPSY; LIVER FIBROSIS; LIVER NECROSIS; MAJOR CLINICAL STUDY; MALE; MOOD DISORDER; MULTICENTER STUDY; MYALGIA; NAUSEA; OPEN STUDY; PAIN; PRIORITY JOURNAL; PRURITUS; RACE; RACE DIFFERENCE; RASH; RIGOR; SINUSITIS; SORE THROAT; SUSTAINED VIROLOGICAL RESPONSE; VIRUS LOAD; VIRUS TYPING; VOMITING; XEROSTOMIA;

ADULT; AFRICAN AMERICANS; AGED; ANTIVIRAL AGENTS; FEMALE; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RIBAVIRIN;

EID: 2542590982     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.20212     Document Type: Article

References (31)

1. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999;341:556-562.
2. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745-750.
3. Man R, Smart R, Anglin L, Adlaf E. Reductions in cirrhosis deaths in the United States: associations with per capita consumption and AA membership. J Stud Alcohol 1991;52:361-365.
4. Howell C, Jeffers L, Hoofnagle JH. Hepatitis C in African Americans: summary of a workshop. Gastroenterology 2000;119:1385-1396.
5. Reddy KR, Hoofnagle JH, Tong MJ, Lee WM, Pockros P, Heathcote EJ, et al. Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group. HEPATOLOGY 1999;30:787-793.
6. McHutchison JG, Poynard T, Pianko S, Gordon SC, Reid AE, Dienstag J, et al. The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group. Gastroenterology 2000;119:1317-1323.
7. Fleckenstein J, Ismail M, Bockhold K, et al. African-American response rate to therapy for hepatitis C [Abstract]. HEPATOLOGY 1998;28:482A.
8. Di Bisceglie AM, Hoofnagle JH. Optimal therapy of hepatitis C. HEPATOLOGY 2002;36(Suppl 1):S121-7.
9. Mann MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-965.
10. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982.
11. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. HEPATOLOGY 1981;1:431-435.
12. Berg T, Sarrazin C, Herrmann E, Hinrichsen H, Gerlach T, Zachoval R, et al. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. HEPATOLOGY 2003;37:600-609.
13. Kinzie JL, Naylor PH, Nathani MG, Peleman RR, Ehrinpreis MN, Lybik M, et al. African Americans with genotype 1 treated with interferon for chronic hepatitis C have a lower end of treatment response than Caucasians. J Viral Hepat 2001;8:264-269.
14. De Maria N, Colantoni A, Idilman R, Friedlander L, Harig J, Van Thiel DH. Impaired response to high-dose interferon treatment in African-Americans with chronic hepatitis C. Hepatogastroenterology 2002;49:788-792.
15. Yamada G, Takatani M, Kishi F, Takahashi M, Doi T, Tsuji T, et al. Efficacy of interferon alfa therapy in chronic hepatitis C patients depends primarily on hepatitis C virus RNA level. HEPATOLOGY 1995;22:1351-1354.
16. Orito E, Mizokami M, Nakano T, Terashima H, Nojiri O, Sakakibara K, et al. Serum hepatitis C virus RNA level as a predictor of subsequent response to interferon-alpha therapy in Japanese patients with chronic hepatitis C. J Med Virol 1994;44:410-414.
17. Knolle PA, Kremp S, Hohler T, Krummenauer F, Schirmacher P, Gerken G. Viral and host factors in the prediction of response to interferon-alpha therapy in chronic hepatitis C after long-term follow-up. J Viral Hepat 1998;5:399-406.
18. Gluck T, Seelig R, Dette S, Buhring HJ, Renz M, Kwon S, et al. Parameters predicting response to alpha-interferon treatment in chronic hepatitis C. Hepatogastroenterology 1997;44:484-491.
19. Davis GL, Lau JY. Factors predictive of a beneficial response to therapy of hepatitis C. HEPATOLOGY 1997;26(Suppl):122S-127S.
20. Layden-Almer J, Ribeiro R, Wiley T, Perelson A, Layden T. Viral dynamics and Response differences in HCV-infected African American and white patients treated with IFN and Ribavirin. HEPATOLOGY 2003;37:1343-1350.
21. Lee SS, Heathcote EJ, Reddy KR, Zeuzem S, Fried MW, Wright TL, et al. Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD). J Hepatol 2002;37:500-506.
22. Zeuzem S, Lee JH, Franke A, Ruster B, Prummer O, Herrmann G, et al. Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa. HEPATOLOGY 1998;27:1149-1156.
23. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1485-1492.
24. Poynard T, McHutchison J, Davis GL, Esteban-Mur R, Goodman Z, Bedossa P, et al. Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. HEPATOLOGY 2000;32:1131-1137.
25. Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002;122:1303-1313.
26. Schvarcz R, Glaumann H, Reichard O, Weiland O. Histological and virological long-term outcome in patients treated with interferon-alpha2b and ribavirin for chronic hepatitis C. J Viral Hepat 1999;6:237-242.
27. Shiratori Y, Imazeki F, Moriyama M, Yano M, Arakawa Y, Yokosuka O, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000;132:517-524.
28. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. HEPATOLOGY 2003;38:1449-1457.
29. Reed WW, Diehl LF. Leukopenia, neutropenia, and reduced hemoglobin levels in healthy American blacks. Arch Intern Med 1991;151:501-505.
30. Zezulka AV, Gill JS, Beevers DG. 'Neutropenia' in black west Indians. Postgrad Med J 1987;63:257-261.
31. Russo M, Fried M. Side effects of therapy of chronic hepatitis C. Gastroenterology 2003;124:1711-1719.